Abstract

Large‐scale screening of sequential drug combinations, wherein the dynamic rewiring of intracellular pathways leads to promising therapeutic effects and improvements in quality of life, is essential for personalized medicine to ensure realistic cost and time requirements and less sample consumption. However, the large‐scale screening requires expensive and complicated liquid handling systems for automation and therefore lowers the accessibility to clinicians or biologists, limiting the full potential of sequential drug combinations in clinical applications and academic investigations. Here, a miniaturized platform for high‐throughput combinatorial drug screening that is “pipetting‐free” and scalable for the screening of sequential drug combinations is presented. The platform uses parallel and bottom‐up formation of a heterogeneous drug‐releasing hydrogel microarray by self‐assembly of drug‐laden hydrogel microparticles. This approach eliminates the need for liquid handling systems and time‐consuming operation in high‐throughput large‐scale screening. In addition, the serial replacement of the drug‐releasing microarray‐on‐a‐chip facilitates different drug exchange in each and every microwell in a simple and highly parallel manner, supporting scalable implementation of multistep combinatorial screening. The proposed strategy can be applied to various forms of combinatorial drug screening with limited amounts of samples and resources, which will broaden the use of the large‐scale screening for precision medicine.

Highlights

  • Finding effective drug combinations for a patient gene­ rally requires unbiased large-scale screening.[14,15] Treating diseases with multiple drugs leads to more complex the number of cells obtained from a patient is usually limited; and elaborate cellular pathway regulation.[1]

  • We developed a bottom-up formation method of heterogeneous drug microarray that was formed by the self-assembly of encoded drug-laden microparticles (DLPs) on a microwell array (Figure 1b)

  • We demonstrated a sequential combinatorial screening of a targeted inhibitor followed by genotoxin against triple-negative breast cancer (TNBC), which is known to be an especially highly resistant form of breast cancer

Read more

Summary

Introduction

Finding effective drug combinations for a patient gene­ rally requires unbiased large-scale screening.[14,15] Treating diseases with multiple drugs leads to more complex the number of cells obtained from a patient is usually limited; and elaborate cellular pathway regulation.[1].

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call